WHEL-C-164 · Moderate evidence · 6/10

estrogen for menopause

A clinical review reports that systemic estrogen reduces menopausal vasomotor symptom frequency by approximately 75% and is first-line therapy for vasomotor and GSM symptoms.

Origin · Existing drug · repurposing candidatePathway · 505(b)(2) · existing active ingredient, new indicationEvidence arm · Direct researchEvidence supports

How to read thisThe summary above and the proposed mechanism are generated by the model from the sources it ingested, and are written as the model’s reasoning rather than established fact. Any figure quoted from MATRIX is a model-derived association score, not a clinical measurement. How far the published record backs this pair is carried by the score’s own rigor dimension and traced to verbatim sources at the foot of the page.

Hypothesized mechanism

Estrogen replacement restores declining ovarian estrogen, relieving menopausal vasomotor and genitourinary symptoms.

This is the model’s proposed mechanism from the sources on file, not a demonstrated causal pathway. How well the published record supports it is reflected in the rigor and plausibility dimensions of the score, and traced to the verbatim sources at the foot of the page.

How the score was reached, for this pair

The composite score is the sum of five dimensions, each scored 0 to 2 by the model from the evidence on file. Below is the sub-score this specific pair received on each, with what that dimension measures. It scored 6 of 10 overall, a moderate reading, from a direct rated moderate in strength.

The model’s overall reasoning for this pair is the summary at the top of the page, and the mechanism it proposed is in the section above.

Direct research arm · anchors the headline6.0 / 10 · Moderate

Scored for women. Evidence generated in women (female population). (band F1, ×1.00).

Corroboration

All claims derive from a single source, a narrative/clinical review ('Management of Menopausal Symptoms: A Review'). A single review is not independent replication, and no distinct studies are cited, so this scores 1 at most.

1 / 2

Rigor

The source is a review article asserting efficacy figures and first-line recommendations, but it is not described as a systematic review or meta-analysis with pooled rigor, nor an RCT. It reads as a narrative clinical review, supporting a score of 1.

1 / 2

Specificity

Both the intervention (systemic/oral/transdermal estrogen) and the condition (menopausal vasomotor symptoms and GSM) are named directly in the claims. The link between estrogen and menopausal symptoms is explicit.

2 / 2

Plausibility

The claims assert quantitative efficacy (~75% reduction) and first-line status but do not articulate a mechanism (estrogen replacement of declining ovarian output). The mechanism is plausible and well-known but not spelled out in the verified quotes.

1 / 2

Consistency

Only a single source is provided, so cross-study consistency cannot be assessed; per rule a single source scores 1. The claims are internally directionally consistent (all positive for estrogen efficacy).

1 / 2

How the scoring rubric works, in general →

Layers not covered for this pair

Sex-specific pharmacokineticsNone on file

Not covered for this pair. This layer holds documented sex-specific pharmacokinetics for a limited set of drugs, and this compound is not among them yet. A blank here means the drug is not covered by the layer, not that no sex difference exists.

More on the sex-specific pharmacokinetics layer and its sources →

Cycle-phase dependenceNone on file

Not covered for this pair. The cycle-phase layer is seeded for the strongest-evidence cases so far (PMDD), and this pair is not among them yet. A blank here means the pair is not covered by the layer, not that the effect was found to be phase-independent.

More on the cycle-phase layer and its sources →

Source evidence · what the pipeline ingested

These are the sources the pipeline ingested to detect and score this signal, the published literature the model actually read, each tagged by study type. Where the model combined findings the claim is marked as a synthesis (S), and where the literature disagrees the contradiction is shown (!).

Every source below belongs to this signal’s evidence arm, Direct research. Whel reads each drug-condition pair through four such arms, each held to its own inclusion bar; a signal is surfaced through one of them.

1Systemic estrogen alone or combined with a progestogen reduces the frequency of vasomotor symptoms by approximately 75%. PubMed · PMID 36749328 ↗
2Oral and transdermal estrogen have similar efficacy. PubMed · PMID 36749328 ↗
3Hormonal therapy with estrogen is the first-line therapy for bothersome vasomotor symptoms PubMed · PMID 36749328 ↗
4Hormonal therapy with estrogen is the first-line therapy for bothersome vasomotor symptoms and GSM symptoms PubMed · PMID 36749328 ↗

These are the verbatim sources the pipeline surfaced and read; they may not be the full published record for a pair, and the score reflects the strength and agreement of the evidence rather than its volume. The strength of these source types is what the rigor dimension of the score reads off. MATRIX, sex-specific pharmacokinetics, and cycle phase are separate layers the pipeline does not ingest, external cross-references reported beside the score, and they link to their own sources in their sections above.

The primary sources and pipelines this evidence is drawn from →

← Back to the full index